



Updated: 06/2022
DMMA Approved: 08/2022

Request for Prior Authorization for Zulloresso (brexanolone)
Website Form – www.highmarkhealthoptions.com
Submit request via: Fax - 1-855-476-4158

All requests for Zulloresso (brexanolone) require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Zulloresso (brexanolone) Prior Authorization Criteria:

Coverage may be provided with a diagnosis of Postpartum Depression (PPD) and the following criteria is met:

- Must be age-appropriate according to FDA-approved labeling, nationally recognized compendia, or evidence-based practice guidelines
- Must be ≤ 6 months postpartum
- Onset of symptoms was in the third trimester or within 4 weeks of delivery
- Hamilton Rating Scale for Depression (HAM-D) ≥ 20
- Member has been counseled on the monitoring requirements and side effects of the medication and has provided consent to treatment
- Must not have a medical history of schizophrenia, bipolar disorder, or schizoaffective disorder
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 1 week
- **Reauthorization criteria**
 - One-time use per pregnancy
- **Reauthorization Duration of Approval:** N/A

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

Drugs are authorized in generic form unless the branded product is on the preferred drug list or the prescriber has indicated in writing that the branded product is medically necessary. If only the branded product is on the preferred drug list, the generic form will be considered non-preferred and shall not require the prescriber to indicate in writing that the branded product is medically necessary.

**ZULRESSO (BREXANOLONE)
PRIOR AUTHORIZATION FORM**

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Health Options Pharmacy Services. **FAX:** (855) 476-4158
If needed, you may call to speak to a Pharmacy Services Representative. **PHONE:** (844) 325-6251 Mon-Fri 8:00am to 7:00pm

PROVIDER INFORMATION

Requesting Provider:	NPI:
Provider Specialty:	Office Contact:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:	
Member ID:	Member weight:	Height:

REQUESTED DRUG INFORMATION

Medication:	Strength:	
Directions:	Quantity:	Refills:
Is the member currently receiving requested medication? <input type="checkbox"/> Yes <input type="checkbox"/> No		Date Medication Initiated:
Is this medication being used for a chronic or long-term condition for which the medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No		

Billing Information

This medication will be billed: at a pharmacy **OR** medically, JCODE: _____
Place of Service: Hospital Provider's office Member's home Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Diagnosis:
 Postpartum Depression, ICD-10 Code: _____
 ➢ How many months postpartum is the member currently? ≤ 6 months more than 6 months
 ➢ When did symptoms start? Third trimester Within 4 weeks of delivery Other: _____
 ➢ HAM-D Score: 0 - 20 20 - 50
 Other: _____ ICD-10 Code: _____

Has the member been counseled on the monitoring requirements and side effects and provided consent to treatment?
 Yes No

Does the member have a history of schizophrenia, bipolar disorder, or schizoaffective disorder? Yes No

CURRENT or PREVIOUS THERAPY

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

SUPPORTING INFORMATION or CLINICAL RATIONALE

Prescribing Provider Signature

Date

--	--



Updated: 06/2022
DMMA Approved: 08/2022



Updated: 06/2022
DMMA Approved: 08/2022



Updated: 06/2022
DMMA Approved: 08/2022